Claims for Patent: 10,098,860

Summary for Patent: 10,098,860

Title:	Bezafibrate for the treatment of cancer
Abstract:	Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
Inventor(s):	Malhotra; Geena (Mumbai, IN), Joshi; Kalpana (Maharashtra, IN), Ghosalkar; Jeevan (Thane, IN)
Assignee:	Cipla Limited (Mumbai, IN)
Application Number:	15/653,814
Patent Claims:	1. A method for the treatment of renal cell carcinoma in a patient, the method comprising administering to said patient bezafibrate, or a pharmaceutically acceptable salt or prodrug thereof, in an amount effective to treat renal cell carcinoma. 2. The method according to claim 1, wherein the renal cell carcinoma comprises treat conventional (clear-cell) renal cell carcinoma, papillary renal cell-carcinoma, chromophobe renal carcinoma, onco-cytoma, or collecting-duct carcinoma. 3. The method according to claim 1, wherein the renal cell carcinoma comprises Stage I, Stage II, Stage III or Stage IV renal cell carcinoma. 4. The method according to claim 1, wherein bezafibrate is administered in combination with at least one other cancer therapy. 5. The method according to claim 4, wherein the additional cancer therapy comprises surgery, chemotherapy, immunotherapy, or ionizing radiation. 6. The method according to claim 5, wherein the additional cancer therapy comprises administering at least one additional agent comprising a nucleoside analogue, antifolate, antimetabolite, topoisomerase I inhibitor, anthracycline, podophyllotoxin, taxanes, vinca alkaloid, alkylating agent, platinum compound, proteasome inhibitor, nitrogen mustards, oestrogen analogue, monoclonal antibody, tyrosine kinase inhibitor, mTOR inhibitor, retinoid, immunomodulatory agent, histone deacetylase inhibitor, or other kinase inhibitor. 7. The method according to claim 6, wherein the at least one additional agent comprises bevacizumab, axitinib, sorafenib, sunitinib, everolimus, temsirolimus, pazopanib, or lenvatinib. 8. The method according to claim 6, wherein the at least one additional agent comprises sunitinib. 9. The method according to claim 6, wherein the at least one additional agent is administered simultaneously with bezafibrate. 10. The method according to claim 6, wherein the at least one additional agent is administered sequentially with bezafibrate. 11. The method according to claim 6, wherein the at least one additional agent is administered separately from bezafibrate. 12. The method according to claim 4, wherein the bezafibrate is administered prior to treatment with ionizing radiation. 13. The method according to claim 4, wherein the bezafibrate is administered subsequent to treatment with ionizing radiation. 14. The method according to claim 4, wherein the bezafibrate is administered prior to surgical treatment for renal cell carcinoma. 15. The method according to claim 4, wherein the bezafibrate is administered subsequent to surgical treatment for renal cell carcinoma.

Details for Patent 10,098,860

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2036-07-20